A data published by the American Cancer Society; kidney cancer is one of the 10 most common cancers in 10 common cancers in both women and men in the United States. There has been a surge in the establishment of research institutes dedicated to finding efficacious drugs for treating kidney cancer. The recent development of drugs for curing kidney cancer has opened lucrative opportunities for the market players. This blog will explore various aspects associated with the kidney cancer drugs market.
Prominent types of therapies given to patients:
- Targeted drug therapy for kidney cancer
The researchers are gaining knowledge regarding protein and gene changes inside cells that cause them to become cancer cells. In targeted therapy, drugs are used to target some of these changes and are different from standard chemotherapy.
- Treating patients with advanced kidney cancer
It has been estimated that 15 out of 100 people having stage 4 cancer are expected to survive their cancer for 5 years. Numerous targeted drugs can be utilized to treat kidney cancer by blocking proteins called tyrosine kinases inside cancer cells. These drugs are called TKIs or tyrosine kinase inhibitors.
Some examples of drugs that target tumor blood vessel growth are Sunitinib, Votreint, Cabozantinib, Lenvima, Avastin, and Belzutifan. In 2023, the FDA approved belzutifan for advanced for advanced kidney cancer.
- Drugs that target mTOR protein: Some of the examples of drugs that target mTOR protein are Torisel or Temsirolimus and Afinitor.
- Drugs for Immunotherapy
Immunotherapy is a cancer treatment that utilizes medications to boost the immune system of the patient. Some of the prominent types of immunotherapies used for treating kidney cancer are:
- Immune checkpoint inhibitors
Some of the drugs available in the market for conducting this type of immunotherapy are Nivolumab, Ipilimumab, Avelumab, and Pembrolizumab. These drugs act as immune checkpoint inhibitors and prevent cancer cell proteins from binding with T cell proteins. The process of immunotherapy is typically used to treat stage 3 or 4 kidney cancer.
However, every patient reacts differently to immunotherapy and has become an integral part of the management of metastatic kidney cancer.
- Chemotherapy for kidney cancer
Renal cell carcinoma is the most common type of kidney cancer and typically does not respond well to chemo. The above-mentioned treatments are used more frequently than chemotherapy treatment. Some of the drugs used by doctors in chemotherapy to treat kidney cancer include:
- 5-fluorouracil
- Cisplatin
- Doxorubicin
- Vincristine
Kidney Cancer Drugs Market Analysis:
The market is projected to garner USD 6.9 billion by the end of 2024 and the market is anticipated to garner USD 13 billion by the end of year 2037. Some of the growth-propelling factors of the kidney cancer drugs market are written as follows:
- Rising cases of kidney cancer all across the world– According to data published by the National Institutes of Health, kidney cancer is estimated to occur in 400,000 people annually with a global mortality rate reaching 175,100 deaths per year.
- Rising investment in kidney cancer research– According to Congressionally Directed Medical Research Programs during FY17 the United States Congress directed USD 10 million to kidney cancer research. Also, according to the Kidney Cancer Association, almost 87 interventional studies have been conducted since 2023, and the research landscape is full of potential.
- Rising awareness of kidney cancer- According to the American Association for Cancer Research, March is Kidney Cancer Awareness Month. Governments all across the world are making people aware of various aspects of kidney cancer such as, if diagnosed timely and by taking appropriate drugs, the ailments can be cured.
Additionally, the North American drugs market accounted for USD 2.2 billion in revenue. The growth in the region is driven by humongous healthcare expenditures and the presence of more aware people.
Some of the prominent companies in the domain are AbbVie, Arlak Biotech, Apikos Pharma, Astellas Pharma, AstraZeneca Plc, Amgen Inc, GlaxoSmithKline Inc, Byer AG, Johnson & Johnson, and Novo Nordisk A/S.
The latest developments in the field of medicine in renal cancer treatment are:
- RCC has recently approved a combination of targeted therapy with an ICI (immune checkpoint inhibitor)
- Stereotactic body radiotherapy renders an efficacious treatment alternative for early-stage RCC
- FDA-approved drugs for targeting the VHL gene pathway
- A recently approved drug called Belzutifan renders new treatment options
On the back of these burgeoning innovations and growth aspects, numerous market players are investing huge amounts in the market and rendering stupendous results.
Wrapping,
The above discussion illustrates that the market is offering lucrative opportunities for growth and opening numerous avenues. However, the market players are required to understand the intricacies of the market and understand market dynamics deeply. The best way to understand the market parameters is to avail yourself of an all-inclusive market research report. These reports consist of regional analysis, market growth drivers, latest trends, key market players, growth revenue parameters, etc.
Source: https://www.researchnester.com/reports/kidney-cancer-drugs-market/6399
By Aashi Mishra, Research Writer at Research Nester
Author –
Aashi Mishra
An experienced research writer, strategist, and marketer with a demonstrated history of research in a myriad of industries. I love to distill complex industrial terminologies of market space into simpler terms.